Why 2026 Part D Plans Are Tightening Prior Auth Documentation for Cell and Gene Therapies After CMS’s New Supplemental Benefit Reporting Rule
The 2026 Medicare Part D plan year brings a real shake-up in how prior authorization (PA) is handled for cell and gene therapies. The shift stems from a Centers for Medicare & Medicaid Services (CMS) requirement expanding supplemental benefit reporting starting with this contract year. That rule forces plans to spell out, not just reference, their utilization management criteria and the documentation standards they use for high-cost drugs. In practice, it means sponsors are reworking PA workflows and documentation templates to satisfy CMS’s transparency tests, especially for therapies that can run north of $1 million a dose.
New CMS Reporting Structure for 2026
Beginning this year, CMS mandates that Part D sponsors submit standardized data on supplemental benefit use and prior authorization protocols under the 2025 final rule (CMS-4206-F). The goal is to align those plan-level submissions with the Inflation Reduction Act’s drug pricing program and the more detailed manufacturer rebate reporting now required. For the first time ever, MA-PD and standalone PDPs have to disclose how their documentation requirements or clinical review rules differ from the evidence-based compendia used for cellular, genetic, or regenerative therapies.
Plans also must demonstrate how their PA standards coordinate with the new negotiated-drug list and cost-sharing protections like the $2,000 annual out-of-pocket cap that landed in 2025. CMS made it clear that incomplete or obscure documentation could trigger enforcement actions because it might be used to limit access to approved high-cost therapies on the Part D formulary.
Why Cell and Gene Therapies Trigger More Documentation
These therapies are highly individualized and usually flow through limited-distribution channels. Zolgensma for spinal muscular atrophy lists above $2 million per infusion and sits on most specialty tiers as a tier 5 therapy. Zynteglo and Hemgenix fall in a similar cost range. Because these are often one-time treatments, payers demand proof, and a lot of it, that a beneficiary meets FDA-labeled indications. For 2026, more plans require actual genetic reports, baseline data, plus evidence the treatment center holds specialty accreditation. That stack of evidence can run dozens of pages deep.
Before 2026, some sponsors leaned heavily on manufacturer checklists or basic ICD-10 matches. That standard doesn’t fly under the new CMS data mandate. Plans now have to show that PA criteria follow clinical logic, and their internal review committees must meet CMS’s expedited 72-hour timeframe for Part D determinations. Look, it's bureaucracy with a purpose, but it’s still bureaucracy.
Comparison: Prior Authorization Frameworks from 2025 vs. 2026
| Category | 2025 Part D (Historical) | 2026 Part D (Current) |
|---|---|---|
| Reporting Requirement | Plans self-reported PA methods in narrative form | Standardized CMS submission of PA and documentation templates linked to supplemental benefits |
| Clinical Evidence Source | Manufacturer labeling or compendia citation | Explicit documentation showing lab, diagnostic, or genomic evidence supporting approval |
| CMS Oversight | Audit-based sampling of UM policies | Annual submission reviewed alongside OOP-cap data and negotiated-drug list compliance |
| Beneficiary Reporting | Limited access to PA rationale | Plan must disclose PA criteria on its Medicare Plan Finder entry and provide patient-facing rationale upon request |
| Turnaround Time Documentation | Tracked internally | Reported to CMS quarterly for therapies above $500,000 in annualized cost |
Impact on Patients, Pharmacists, and Benefit Managers
Patients feel the brunt first, more paperwork before approval. Genetic testing, attestations from specialists, even lab-verification letters. CMS says each must be clinically justified, not just red tape. But still, approvals stretch two to three weeks in many legitimate cases, which feels like forever when you’re waiting on a potential cure.
Pharmacists now face extra verification steps, too. Specialty pharmacies handling CAR-T products like Kymriah and Abecma must confirm prescribers submitted CMS-compliant forms. Miss a detail and a claim can bounce or later raise audit flags. Pharmacies also upload documentation verifying chain-of-custody timelines and infusion completions to fit CMS’s expanded utilization reporting. Tedious, yes, but required.
Then come the benefits managers. For retiree MA-PD groups especially, data management obligations have ballooned. They must maintain auditable PA documentation proving fair application across members, ready for CMS audits or negotiation-effectiveness reviews. Appeals, grievance reports, timelines, everything hits the 2026 CMS standard clock. Compliance by spreadsheet, basically.
Administrative Concerns and Plan Variation
Insurers argue the transparency rule adds real cost. A 2025 Kaiser Family Foundation survey found about 63 percent of Part D sponsors expected PA processing times to stretch roughly 20 percent after the 2026 rules landed. Large carriers like CVS Health and Elevance are automating document intake systems to offset the workload. Smaller regionals? Still piecing together provider EHR connections, and that gap shows.
Variation is becoming an operational fault line. Nationals lean toward standardized checklists coded directly to CMS fields; smaller players still rely on manual uploads. The outcome: uneven turnaround times. CMS is watching it closely through this year’s Star Rating adjustment factors, especially around appeals and denial metrics.
The Broader Policy Context
This stricter PA world is also about the Inflation Reduction Act’s launch phase. By 2026, the first ten negotiated drugs appear on formularies with capped fair prices. CMS now uses the expanded benefit reporting data to track how cell and gene therapies shape reinsurance spending under those caps. If one therapy blows through catastrophic limits, plans must show how their PA documentation kept use appropriate. Those disclosures will influence whether future gene therapies jump from Part D coverage into value-based designs under Medicare Advantage supplemental benefits.
What to Expect Moving Forward
By midyear, expect standardized e-PA forms, CMS audit templates, and public plan-to-plan comparisons on Medicare Plan Finder. The idea: transparency strong enough that differences in PA review are clearly visible. For patients approved for therapies like Breyanzi or Skysona, though, documentation remains intense. Plans must thread the needle, meet CMS’s demand for clinical proof without eroding the member experience tied to updated Star Ratings.
Those who catch up early, physicians, pharmacists, benefits teams, will survive the adjustment better. Sync EHRs to CMS fields. Fill out those genetic records before the review queue. Audit files before submission. Because 2026 marks the first real cycle where administrative precision directly shapes access to medicine priced like real estate.
Disclaimer: This content is for informational purposes only and does not constitute legal, medical, or insurance advice. Readers should confirm current CMS regulations, formulary status, and coverage details with their plan sponsors or professional advisors.